ArticleBMC pregnancy and childbirth2019
The importance of the PD-1/PD-L1 pathway at the maternal-fetal interface.
Article in BMC pregnancy and childbirth, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 99 citations in OpenAlex.
- Refractory ultra-high-risk Choriocarcinoma achieving complete response to intensive multi-agent and intrathecal chemotherapy and anti-PD-L1 therapy.Gynecologic oncology reports · 2026Article
- Blood-based biomarker discovery for early pregnancy loss using integrative multi-omics strategies.EBioMedicine · 2026Article
- Evaluation of Th1-Th2 balance in patients with recurrent implantation failure; a systematic review and meta-analysis.BMC immunology · 2026Review
- Regulation of the maternal immune system during early bovine pregnancy.Reproduction & fertility · 2026Review
- Multi-omics biomarkers in female fertility: from oocyte quality to endometrial receptivity and clinical translation.Biomarker research · 2026Review
- Checkpoint Inhibition in Gestational Trophoblastic Neoplasia: A Narrative Review on the Reawakening of Antitumor Immunity.Advances in therapy · 2026Review
- Impact of immune checkpoint inhibitors on pregnancy: current evidence and future directions.BMJ oncology · 2026Review
- Role of PD-L1 in the Pathogenesis of Pre-Eclampsia and Its Association with Adverse Fetal Outcomes.Turk patoloji dergisi · 2026Article
- Phenotype- and phase-directed immune interpretation in recurrent implantation failure and pregnancy loss: an integrative framework.Frontiers in reproductive health · 2026Review
- Immune Cells in Preeclampsia.International journal of molecular sciences · 2025Review
- Metabolomic analysis of the endometrium of Large White and Meishan pigs reveals differences in biological processes during late gestation.BMC genomics · 2025Article
- Molecular and cellular morphology of placenta unveils new mechanisms of reproductive immunology.Journal of advanced research · 2025Article
- Nanomedicine targeting the PD-1/PD-L1 axis in autoimmune diseases: breaking conventional barriers to restore immune tolerance.Journal of nanobiotechnology · 2025Review
- Differential Immune Checkpoint Expression in CD4International journal of molecular sciences · 2025Article
- Serum Proteomic Signatures of Pregnancy-associated Breast Cancer.Cancer genomics & proteomics · 2025Article
- MicroRNA-155 targets p65 to regulate PD-L1 expression in the early pregnancy endometrium.Scientific reports · 2025Article
- PD1+ T Regulatory Cells Are Not Sufficient to Protect from Gestational Hypertension.International journal of molecular sciences · 2025Article
- Regulatory B-Cells Are Associated Negatively With Regulatory T-Cells and Positively With Cytokines in Peripheral Blood of Pregnant Women.American journal of reproductive immunology (New York, N.Y. : 1989) · 2025Article
- Decreased PD-L1 contributes to preeclampsia by suppressing GM-CSF via the JAK2/STAT5 signal pathway.Scientific reports · 2025Article
- Immunological reference intervals in pregnancy: longitudinal analysis of adaptive lymphocyte subsets.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundOur goal with this study was to investigate the contribution of PD-1/PD-L1 immune-checkpoint pathway to maternal immunotolerance mechanisms.
methodsThirteen healthy pregnant women and 10 non-pregnant controls were involved in this project. PBMCs and DICs were isolated from peripheral blood and from decidual tissues. After the characterization of different immune cell subsets, we used fluorochrome-conjugated monoclonal antibodies to measure the expression level of PD-1, PD-L1, NKG2D, and CD107a molecules by flow cytometry.
resultsWe measured significant alternations in the proportion of decidual immune cell subsets compared to the periphery. Elevated PD-1 expression by decidual CD8+ T, CD4+ T, and NKT-like cells were also detected accompanied by the increased PD-L1 expression by decidual CD4+ T, Treg, NKT-like and CD56 + NK cell subsets compared to peripheral blood. The cytotoxic potential was significantly higher in PD-1- decidual immune cells compared to the periphery, however we measured a significantly lower cytotoxicity in the decidual PD-1+ CD8+ T cells compared with the peripheral subsets. An activation receptor NKG2D expression was decreased by the PD-1+ CD8+ T subsets in the first trimester compared to non-pregnant condition but the expression level of the decidual counterparts was significantly elevated compared to the periphery. The cytotoxic potential of decidual PD1/NKG2D double positive CD8+ T cells was significantly decreased compared to the peripheral subsets.
conclusionsBased on our results we assume that PD-1/PD-L1 pathway might have a novel role in the maintaining of the local immunological environment. Accompanied by NKG2D activating receptor this checkpoint interaction could regulate decidual CD8 Tc cell subsets and may contribute maternal immunotolerance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.